The in vivo assessment of nimesulide cyclooxygenase-2 selectivity

Rheumatology

Volumn 38, Issue SUPPL. 1, 1999, Pages 19-23

  Shah, A A ^b   Murray, F E ^b   Fitzgerald, D J ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b NONE

Author keywords

COX 2; Cyclooxygenase; NSAIDs

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ARACHIDONIC ACID; CYCLOOXYGENASE 2; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN E2; THROMBOXANE B2;

ANTIINFLAMMATORY ACTIVITY; CONFERENCE PAPER; DIGESTIVE SYSTEM INJURY; DRUG EFFICACY; ENZYME INHIBITION; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; STOMACH; THROMBOCYTE AGGREGATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONAMIDES; THERAPEUTIC EQUIVALENCY;

EID: 0032699240     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/38.suppl_1.19     Document Type: Conference Paper

References (47)

1. Gross M, Greenberg LA. The salicylates. A critical bibliographic review. New Haven, CT: Hillhouse Press, 1984:95.
2. Coggan D, Langman MJS, Spiegelhalter D. Aspirin, paracetamol, haematemesis and melaena. Gut 1982;23: 340-4.
3. Coggan D, Lambert DP, Langman M. 20 years of hospital admissions with peptic ulcer in the United Kingdom. Lancet 1981;i:1302-4.
4. Somerville K, Faulkner G, Langman M. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet 1986;i:462-6.
5. Walt R, Katschinski B, Logan R, Ashley J, Langman M. Rising frequency of ulcer perforation in elderly people in the United Kingdom. Lancet 1986;i:489-92.
6. Bateman DN. NSAIDs: time to re-evaluate gut toxicity. Lancet 1994;343:1051-2.
7. Paulus HE. FDS Arthritis Advisory Committee meeting: post-marketing surveillance of NSAIDs. Arthritis Rheum 1985;28:1168-9.
8. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971;231: 232-5.
9. 2. Scand J Gastroenterol 1981;16:647-52.
10. 2. Prostaglandins 1985;30:609-18.
11. Saroseik J, Mizuta K, Slomiany A et al. Effect of acetylsalicylic acid on gastric mucin viscosity, permeability to hydrogen ions, and susceptibility to pepsin. Biochem Pharmacol 1986;35:4291-5.
12. 2 output in human subjects. Ann Intern Med 1987;106:368-71.
13. Fantone JC. Mechanism of chemotactic factor simulation of polymorphonuclear leukocytes: modulation by prostaglandins. In: Higgs GA, Williams TJ, eds. Inflammatory mediators. London: MacMillan, 1985:127-48.
14. Florence AT, Jani PU. Novel oral drug formulations: their potential in modulating adverse events. Drug Safety 1994;10:233-66.
15. Henry D, Lynete L, Lim Y et al. Variability in the risk of gastrointestinal complication with individual NSAID: result of collaborative meta-analysis. Br Med J 1996; 312:1563-6.
16. Caldwell JR. Sucralfate in the relief of gastrointestinal symptoms associated with non-steroidal anti-inflammatory drugs. South Med J 1985;78:938-40.
17. Nash J, Lambert L, Deakin M. Histamine H2 receptor antagonists in peptic ulcer disease: evidence for a prophylactic use. Drugs 1994;47:862-71.
18. Silverstein FE, Graham DY, Senior JR et al. Misoprostol reduces serious complications in patients with rheumatoid arthritis receiving NSAID. Ann Intern Med 1995;123: 241-9.
19. Yeomans ND, Tulassay Z, Juhasz L et al. A comparison of omeprazole with ranitidine for ulcers associated with NSAIDs. N Engl J Med 1998;338:719-26.
20. Hawkey CJ, Karrasch JA, Szcepanski L et al. Omeprazole compared with misoprostal for ulcers associated with NSAIDs. N Engl J Med 1998;338:727-34.
21. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of cyclo-oxygenase in human monocytes. J Biol Chem 1990;265:16737-40.
22. Masferrer JL, Zweifel BS, Seibert K, Needleman P. Selective regulation of cellular cyclo-oxygenase by dexamethasone and endotoxin in mice. J Clin Invest 1990;86:1375-9.
23. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of mitogen responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692-5.
24. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herchman HR. TIS10, a phorbol ester tumour promoter-inducible mRNA from Swiss 3T3 cells, encoding a novel prostaglandin synthase/cyclo-oxygenase homologue. J Biol Chem 1991;22:12866-72.
25. Hamberg M, Svensson J, Samuellson B. Thromboxane: a new group of biologically active compounds derived from prostaglandin endoperoxidase. Proc Natl Acad Sci USA 1975;72:2994.
26. Xie W, Robertson DL, Simmons DL. Mitogen-inducible prostaglandin G/H synthase: a new target for NSAIDs. Drug Dev Res 1992;25:249-65.
27. Masferrer JL, Zweifel BS, Manning PT et al. Selective inhibition of inducible cyclo-oxygenase 2 in vivo is antiinflammatory and non ulcerogenic. Proc Natl Acad Sci USA 1994;91:3228-32.
28. Kurumbail RG, Stevens AM, Stallings WC. Structural basis for selective inhibition of COX-2 by anti-inflammatory agents. Nature 1996;384:644-8.
29. (523)-Val mutation. J Biol Chem 1997; 272:9280-6.
30. Service RF. Closing in on a stomach-sparing aspirin substitute Science 1996;272:9280-6.
31. Engelhardt PM. Differential inhibition of COX-1 and 2 in vitro and pharmacological profile in vivo of NSAID. In: Vane J, Botting J, Botting R, eds. Improved NSAIDs, COX-2 inhibitors. Lancaster: Kluwer Academic Publishers.
32. Murray FE, Shah AA, Thjodleifsson B et al. Comparison of the effects of naproxen and the COX-2 selective NSAID nimesulide, on prostanoid formation in man. Gut 1998; 42(suppl. 1):A6.
33. Cullen L, Kelly K, Coyle D, Forde R, Fitzgerald DJ. Selective suppression of COX-2 during chronic administration of nimesulide in man. Prostaglandins Leukotrienes Essential Fatty Acids 1997;57:52.
34. Glaser K, Sung ML, O'Neill K et al. Etodolac selectively inhibits human PGHS-1 versus PGHS-2. Eur J Pharmacol 1995;281:107-11.
35. Laine L, Sloane R, Ferretti M, Cominelli F. A randomised double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc 1995;42:428-33.
36. Lipscomb GR, Wallis N, Armstrong G, Goodman MJ, Rees WD. Gastric mucosal adaptation to etodolac and naproxen. Aliment Pharmacol Ther 1995;9:379-85.
37. Patroia L, Santucci L, Furno P et al. A four week, double-blind, parallel group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg, and placebo by means of faecal blood loss, endoscopy and symptoms evaluation in healthy volunteers. Br J Rheumatol 1996;35S:61-7.
38. Mahmud T, Rafi SS, Scott DL, Wrigglesworth JM, Bjarnason I. NSAIDs and uncoupling of mitochondrial oxidative phosphorylation. Arthritis Rheum 1996;39: 1998-2003.
39. Engelhardt G, Bogel R, Schnitzler C et al. Meloxicam: influence on archidonic acid metabolism: part I. In vitro finding. Biochem Pharmacol 1996;51:21-8.
40. Barnett J, Chow J, Ives D et al. Purification, characterisation and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys Acta 1994;1209:130-9.
41. Cullen L, Kelly L, O'Connor S, Fitzgerald DJ. Selective cyclooxygenase-2 inhibition by nimesulide in man. J Pharmacol Exp Ther 1998;287:578-82.
42. Marini U, Spotti D. Gastric tolerability of nimesulide. A double-blind comparison of two dosage regimens and placebo. Drugs 1993;46S:249-52.
43. Shah AA, Murray FE, Thjodleifsson B et al. Nimesulide, a selective COX-2 inhibitor, causes less gastrointestinal damage compared with naproxen: a prospective study in human volunteers. Gut 1998;42(suppl. 1):A68.
44. Bjarnason I, Hayllar J, MacPherson A, Russell AS. Side effects of NSAIDs on the small and large intestine in humans. Gastroenterology 1993;104:1832-47.
45. Meling TR, Aadakken L, Roseth A, Osnes M. Faecal calprotectin shedding after short-term treatment with NSAIDs. Scand J Gastroenterol 1996;31:339-44.
46. Riendeau D, Percival MD, Boyce S et al. Biochemical and pharmacological profile of a tetrasubstiuted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol 1997; 121:105-17.
47. Mizuno H, Sakamoto C, Matsuda K et al. Induction of cyclo-oxygenase-2 in gastric mucosal lesion and its inhibition by a specific antagonist delay healing in mice. Gastroenterology 1997;112:387-97.